Study of Azole - Resistant and Cyp51a Gene in Aspergillus Fumigatus
DOI:
https://doi.org/10.3889/oamjms.2018.171Keywords:
Azole-resistant, Cyp51 A gene, Aspergillus fumigatusAbstract
AIM: The main goal of the present study was to find azole-resistant and molecular analysis of cyp51A gene in Aspergillus fumigatus.
MATERIALS AND METHODS: Fifty-eight A. fumigatus strains including environmental, clinical and reference isolates were assessed in this investigation. Azole susceptibility testing for itraconazole and voriconazole was carried out for A. fumigatus isolates. PCR was performed based on cyp51A gene sequence for all isolates.
RESULTS: Susceptibility testing verified the minimum inhibitory concentrations (MICs) for itraconazole (0.125 to 2 µg/ml) and voriconazole (0.125 to 4 µg/ml). Nine (15.5%) A. fumigatus isolates were resistant to voriconazole with MIC 4 µg/ml. A 1500 bp DNA fragment was amplified using cyp51A gene for all tested Aspergillus isolates. The sequences of the fragments showed 99% identity with A. fumigatus cyp51A gene in the GenBank. No point mutation was found at cyp51A gene codons.
CONCLUSION: In the current study, we detected the voriconazile resistant in A. fumigatus isolates. Susceptibility tests should be considered in patients who infected by A. fumigatus.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Garcia-Hermoso D, Alanio A, Cabaret O, Olivi M, Foulet F, Cordonnier C, Costa JM, Bretagne S. High diversity of non-sporulating moulds in respiratory specimens of immunocompromised patients: should all the species be reported when diagnosing invasive aspergillosis? Mycoses. 2015; 58:557-64. https://doi.org/10.1111/myc.12356 PMid:26214496
Vaknin Y, Hillmann F, Iannitti R, Ben Baruch N, Sandovsky-Losica H, Shadkchan Y, Romani L, Brakhage A, Kniemeyer O, Osherov N. Identification and characterization of a novel Aspergillus fumigatus Rhomboid Family putative protease, RbdA, involved in hypoxia sensing and virulence. Infect Immun. 2016; 8:1866-78. https://doi.org/10.1128/IAI.00011-16 PMid:27068092 PMCid:PMC4907145
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:327-60. https://doi.org/10.1086/525258 PMid:18177225
Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, MartÃnez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001; 45: 2676-84. https://doi.org/10.1128/AAC.45.10.2676-2684.2001 PMid:11557454 PMCid:PMC90716
Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998; 42:241-53. PMid:9527767 PMCid:PMC105395
Brillowska-Dąbrowska A, Mroczyńska M, Nawrot U, Włodarczyk K, Kurzyk E. Examination of cyp51A and cyp51B expression level of the first Polish azole resistant clinical Aspergillus fumigatus isolate. Acta Biochim Pol. 2015; 62(4):837-9. https://doi.org/10.18388/abp.2015_1143 PMid:26636140
Araujo R, Gungor O, Amorim A. Single-tube PCR coupled with mini-sequencing assay for the detection of cyp51A and cyp51B polymorphisms in Aspergillus fumigatus. Future Microbiol. 2015; 10:1797-804. https://doi.org/10.2217/fmb.15.103 PMid:26515651
Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009; 15:1068-76. https://doi.org/10.3201/eid1507.090043 PMid:19624922 PMCid:PMC2744247
Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9:789-95. https://doi.org/10.1016/S1473-3099(09)70265-8
Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008; 5:e219. https://doi.org/10.1371/journal.pmed.0050219 PMid:18998768 PMCid:PMC2581623
Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother. 2015; 59:7224-31. https://doi.org/10.1128/AAC.01698-15 PMid:26349818 PMCid:PMC4649151
Lewis RE, Verweij PE. Animal Models for Studying Triazole Resistance in Aspergillus fumigatus. J Infect Dis. 2017; 216(Suppl 3):S466-S473. https://doi.org/10.1093/infdis/jix222 PMid:28911046
Pfaller MA, Messer SA, Karlsson A, Bolmström A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol. 1998; 36:2586-9. PMid:9705397 PMCid:PMC105167
Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009; 12:141-7. https://doi.org/10.1016/j.drup.2009.09.002 PMid:19879181
Mellado, E, Alcazar-Fuoli L, Garcia-Effron G, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela J L. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med. Mycol. 2006; 44(Suppl.):367–371. https://doi.org/10.1080/13693780600902243
Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007; 44:531-40. https://doi.org/10.1086/510592 PMid:17243056
Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41:1364-8. PMid:9174200 PMCid:PMC163916
Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.Clin Microbiol Infect. 2001; 7: 130-7. https://doi.org/10.1046/j.1469-0691.2001.00220.x PMid:11318811
Paul A. Mann, Raulo M. Parmegiani, Shui-Qing Wei, Cara A. Mendrick, Xin Li, David Loebenberg, Beth DiDomenico, Roberta S. Hare, Scott S. Walker, and Paul M. McNicholas. Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase.Antimicrob Agents Chemother. 2003; 47:577–581. https://doi.org/10.1128/AAC.47.2.577-581.2003 PMid:12543662 PMCid:PMC151774
Nascimento AM, Goldman GH, Park S, Marras SA, Delmas G, Oza U, Lolans K, Dudley MN, Mann PA, Perlin DS. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003; 47:1719-26. https://doi.org/10.1128/AAC.47.5.1719-1726.2003 PMid:12709346 PMCid:PMC153329
Ren-ai Xu, Shuang-li Zheng, Li-li Xiao, Xue-ding Cai, Xi-xi Lai, Guan-yang Lin, Lu-feng Hu, Chun-hong Zhang, Zhi-sheng Xu, Xiu-hua Zhang. Therapeutic drug monitoring in voriconazole-associated hyponatremia. Med Mycol Case Rep. 2013; 2: 134–136. https://doi.org/10.1016/j.mmcr.2013.06.003 PMid:24432238 PMCid:PMC3885944
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
